SCHEMBL283130

SCHEMBL283130

Nc1cccc(C(F)(F)F)c1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.41
HTT P42858 1/20 0.41
MMP2 P08253 1/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CFTR P13569 1/20 0.40
TAS2R14 Q9NYV8 2/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
PTGS1 P23219 1/20 0.39
FABP4 P15090 1/20 0.39
PLK1 P53350 1/20 0.39
PLK3 Q9H4B4 1/20 0.39
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4454152 0.98 HSD17B10 (0.41) HSD17B10HTTMMP2ALDH1A1HPGD
Water SCHEMBL356237 0.98 HSD17B10 (0.41) HSD17B10HTTMMP2ALDH1A1HPGD
SCHEMBL504216 0.86 CA12 (0.46) ALDH1A1HPGDTAS2R14CA12CA1
SCHEMBL4095197 0.85 PTGS1 (0.39) HSD17B10HTTALDH1A1HPGDKDM4E
SCHEMBL23908702 0.82 ALDH1A1 (0.51) ALDH1A1HPGDTAS2R14CA12CA1
Hydrochloric Acid SCHEMBL9874294 0.81 THRB (0.39) HSD17B10HTTALDH1A1TAS2R14PTGS1
SCHEMBL10489765 0.81 GLRA3 (0.46) HSD17B10MMP2ALDH1A1KDM4ECA12
SCHEMBL8570598 0.80 CFTR (0.49) HSD17B10ALDH1A1HPGDKDM4ECFTR
SCHEMBL11692958 0.79 CFTR (0.46) CFTRPTGS1PLK1LMNAGAA
SCHEMBL1000014 0.79 MMP2 (0.54) HSD17B10MMP2ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
WO-2016071485-A1 METHOD FOR DETERMINING THE COMPOSITION OF THE SUGAR MOIETY OF A SUGAR CONTAINING COMPOUND DANMARKS TEKNISKE UNIVERSITET (DK) 2016-05-12 WO claimed
US-20090306375-A1 Process for production of 4(3H)-quinazolinone derivative MSD K.K. (JP) 2009-12-10 US claimed
US-20090131664-A1 Method for Producing 4(3H)-Quinazolinone Derivative MSD K.K. (JP) 2009-05-21 US claimed
CN-101351459-A Method for producing 4(3H)-quinazolinone derivative BANYU PHARMA CO LTD (JP) 2009-01-21 CN claimed
EP-1903040-A1 METHOD FOR PRODUCING 4(3H)-QUINAZOLINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-03-26 EP claimed
EP-1900733-A1 PROCESS FOR PRODUCTION OF 4(3H)-QUINAZOLINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-03-19 EP claimed
EP-3968404-B1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORP (US) 2026-04-01 EP disclosed
EP-4678641-A1 QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF Shanghai Helioson Pharmaceutical Co., Ltd. (CN) 2026-01-14 EP disclosed
CN-119585247-A Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain 赛特温治疗公司 2025-03-07 CN disclosed
EP-4514789-A1 <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN SiteOne Therapeutics, Inc. (US) 2025-03-05 EP disclosed
US-20240397810-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-11-28 US disclosed
US-12082485-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-09-03 US disclosed
CN-1556705-A 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives ������˹ҩƷ��˾ 2004-12-22 CN disclosed
WO-2004004733-A1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO[2,1-B]-QUINAZOLINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2004-01-15 WO disclosed
WO-2003106435-A1 FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF SANKYO COMPANY, LIMITED (JP) 2003-12-24 WO disclosed
EP-0572863-A1 CNS pyrazinoindoles F. HOFFMANN-LA ROCHE AG (CH) 1993-12-08 EP disclosed
US-RE31617-E ANTICOAGULANTS; HYPOTENSIVE AND BRONCHODILATOR AGENTS BRISTOL-MYERS COMPANY (US) 1984-06-26 US disclosed
US-4307113-A TREATMENT OF DIABETES SANDOZ, INC. (US) 1981-12-22 US disclosed
US-3932407-A BRONCHODILATORS, HYPOTENSIVE AGENTS, ANTICOAGULANTS BRISTOL-MYERS COMPANY (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12082485-B2 Organic electroluminescent materials and devices ORC3, OCIAD1, ICOSLG HSD17B10 4181/4885HTT 4451/4885MMP2 4757/4885
US-20240397810-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES ORC3, OCIAD1, ICOSLG HSD17B10 4181/4885HTT 4451/4885MMP2 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.